TG and myeloid sarcoma: Despite some factors and small molecules (compounds) being shown to improve myelination in cell cultures, as well as remyelination in animal models, no medication presenting convincing remyelinating capacity in humans has been approved for MS patients so far, with clemastine and analogs of thyroid hormone still having to complete phase III clinical trials23–26.